VENUS®
Enjoy Innovations

VRL/SEC/NSE/92

18.01.2013

National Stock Exchange of India Ltd..
5th Floor , Exchange Plaza
Bandra (E), Mumbai- 400 051

Sub. : VENUS REMEDIES LAUNCHES 'ELORES' - CSE 1034 , A US PATENT PROTECTED PRODUCT IN INDIA

Dear Sir,

We are pleased to inform that the company has launched CSE1034 under the brand name "ELORES" . It is a novel Antibiotic Adjuvant Entity (AAE) to combat antimicrobial resistance caused by MDR, ESBL producing strains.

The product was launched by Dr. K.N. Parsad, Associate Professor, Department of Microbiology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow at Manthan 2013, a seminar-cum-workshop organised by 'Venus Medicine Research Centre' (VMRC). The single-session seminar-cum-workshop was chaired by Dr. Yatin Mehta, Chairman, Medanta Institute of Critical Care and Anesthesiology, Medanta The Medicity, Gurgaon, Haryana which was also attended by the eminent doctors from the healthcare fraternity of India.

Receiving US patent for ELORES was a landmark development to initiate the process of commercialization and today we are launching it in India as ELORES. Designed specifically to target growing bacterial resistance mechanisms, ELORES has a unique profile of action which gives it an edge over all the existing therapies. This unique antibiotics adjuvant entity creates a synergistic effect due to its activity on AMRINGER (Acquired Multiple Resistance in Gram Negative Enterococci and Rods) which stops development and spread of bacterial resistance.

This product is effective against Metallo betalactamases (MBL) producing pathogens which are not susceptible to most of the existing antibiotics. It is also unique in its way that it not only kills resistant pathogens (Bacteria) but also prevents the spread of resistance.

ELORES comprises of a third generation cephalosporin, a beta lactamase inhibitor along with non antibiotic adjuvant Disodium Edetate for intravenous administration. It is effective against MDR pathogen producing ESBLs, MBLs like NDM-01, increases cell permeability while working on Cell impermeability mechanism of MDRs, regulate 'Efflux pump over expression', breaks bacterial 'Biofilms', prevents 'Transfer of resistant plasmid' and hence the spread of resistance is controlled.

The Company is positioning ELORES as the need of the hour as it would be able to reduce a minimum of 30% of the hospitalisation cost and almost 50% of the drug cost, thereby proving to be very beneficial for the patients. As per a study conducted in Delhi, patients with hospital-acquired infections experienced a significantly longer hospital stay (mean: 22.9 days); significantly longer

FROM :VENUS FAX NO. :0172 2565566 18 Jan. 2013 08:59 P 1

intensive care unit (ICU) stay (mean: 11.3 days); a significantly higher mortality (mean: 54%) and cost significantly more (mean: US$ 14, 818) than controls. So, ELORES would be able to curtail these statistics.

The Company has conducted Clinical Trials Phase I, II and III successfully on a large patient population of 654 patients to prove clinical efficacy and safety in ESBL/MBL resistant pathogens.

Currently, India possesses a huge anti-infective market of around INR 8.5 billion. According to a survey, 40% of the antibiotic sales can be attributed to antimicrobial resistance. Of this, 71.5% of the total antimicrobial resistance market comes from the major resistance segment of ESBLs/ MBL resistance (as per a study by AIIMS). The Company want to cater to this segment effectively & immediately and are expecting to capture 10% share of the total AMR market in India in the next 5 years, making it an over INR 2.0 billion product.

Furthermore, ELORES has already secured patents from all over the world including countries like US, Europe, Australia, and Russia. The Company is awaiting registration grant for ELORES with European regulatory bodies to commercialize it there sooner.

For Venus Remedies Limited

Rakesh Pandit
DGM -Investor Relations

VENUS REMEDIES LIMITED

Corporate Office :
51-52, Industrial Area, Phase- I,
Panchkula (Hry.) 134113, India
Regd. Office :
SCO 857, Cabin No. 10, 2nd Floor, NAC,
Manimajra, Chandigarh (U.T.) 160101, India
Website : www.venusremedies.com
www.venusmedicineresearchcentre.com

Unit-I :
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566
Unit-II :
Hill Top Industrial Estate, Jharmajri EPIP, Phase-I, (Extn.),
Bhatoli Kalan, Baddi (H.P.) 173205, India
Tel. : +91-1795-302100, 302101, 302107, Fax : +91-1795-271272
Unit-V :
VENUS PHARMA GmbH
AM Bahnhof 1-3, D-59368 Werne, Germany

FROM :VENUS FAX NO. :0172 2565566 18 Jan. 2013 08:59 P 2